SOURCE Sanofi Pasteur
Pharma group Sanofi rises on improved guidance and RBS gains after a third-quarter profit beat.
Analysts are expecting to see a year-over-year decline in earnings and revenue when Sanofi (SNY) posts 2016 third-quarter results before Friday's market open.
Tech giants, Big Pharma and insurers are all angling to profit from the $3 trillion-plus U.S. healthcare market.
The Danish pharmaceuticals maker is facing tighter margins and tougher competition in the U.S.